Paul Liknaitzky

Paul Liknaitzky is a Senior Research Fellow and Head of the Clinical Psychedelic Lab at Monash University's Department of Psychiatry. He leads Australia's largest psychedelic research group and pioneered clinical psychedelic research in the country, establishing the first psychedelic lab and therapist training programs. His work focuses on psychedelic therapies for mood disorders, addiction, PTSD, and OCD, with notable contributions to psilocybin-anxiety treatment trials and psychedelic-augmented VR therapies. He has secured industry funding and co-founded Australia's first psychedelic-assisted therapy clinic.

• Affiliations: Honorary Research Fellow at Swinburne University and University of Melbourne
• Education: PhD in Psychological Sciences (University of Melbourne), BSc Neuroscience (University of Western Australia)

Research interests include novel psychedelic applications, therapist training, treatment accessibility, and risk assessment. He has led 6 major projects, including trials for MDMA-assisted therapy and psychedelic interventions for anorexia nervosa. His 23 publications cover topics like psychedelic safety, regulatory pathways, and patient experiences. In 2024, he received the Exceptional Achievement Prize. Liknaitzky collaborates internationally and advises on psychedelic policy for government and industry.